Current State of Drug Therapies for Antibody-mediated Rejection After Heart Transplantation.

Antibody-mediated rejection (AMR) continues to be a significant and challenging complication after alternative surgical methods, contributing significantly to morbidity and mortality. Despite its clear clinical impact, there is no consensus on optima…

Preview only. Read the full abstract at the source